share_log

8-K: HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

8-K: HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

8-K：HeartSciences提供最新业务并报告2025财年第一季度财务业绩
美股SEC公告 ·  09/12 13:20

Moomoo AI 已提取核心信息

On September 12, 2024, Heart Test Laboratories, Inc., also known as HeartSciences, reported its financial and operational results for the first quarter of fiscal year 2025, which ended on July 31, 2024. The company, which specializes in AI-powered medical technology for heart disease detection, highlighted the progress of its MyoVista wavECGTM device and MyoVista InsightsTM cloud platform. HeartSciences announced a cash and cash equivalents balance of $4.3 million and shareholder’s equity of $5.9 million. Post-quarter, the company secured $1.9 million in non-dilutive financing and extended a $500,000 loan note. The MyoVista Insights Platform is expected to be completed by the end of 2024, with FDA submission targeted for the second half of 2025. The FDA 510(k) submission for the MyoVista wavECGTM device is on track for early 2025. The company also showcased its technology at the United Nations General Assembly Digital Health Symposium and expanded its intellectual property portfolio. Despite these advancements, HeartSciences reported no revenues for Q1 FY2025. The complete financial results have been filed with the U.S. Securities and Exchange Commission.
On September 12, 2024, Heart Test Laboratories, Inc., also known as HeartSciences, reported its financial and operational results for the first quarter of fiscal year 2025, which ended on July 31, 2024. The company, which specializes in AI-powered medical technology for heart disease detection, highlighted the progress of its MyoVista wavECGTM device and MyoVista InsightsTM cloud platform. HeartSciences announced a cash and cash equivalents balance of $4.3 million and shareholder’s equity of $5.9 million. Post-quarter, the company secured $1.9 million in non-dilutive financing and extended a $500,000 loan note. The MyoVista Insights Platform is expected to be completed by the end of 2024, with FDA submission targeted for the second half of 2025. The FDA 510(k) submission for the MyoVista wavECGTM device is on track for early 2025. The company also showcased its technology at the United Nations General Assembly Digital Health Symposium and expanded its intellectual property portfolio. Despite these advancements, HeartSciences reported no revenues for Q1 FY2025. The complete financial results have been filed with the U.S. Securities and Exchange Commission.
2024年9月12日，Heart Test Laboratories, Inc.，也称为HeartSciences，报告了截至2024年7月31日的2025财年第一季度的财务和运营结果。该公司专注于用人工智能技术进行心脏病检测的医疗技术，重点介绍了其MyoVista wavECGTm设备和MyoVista InsightsTm云平台的进展。HeartSciences宣布现金及现金等价物余额为430万美元，股东权益为590万美元。季度结束后，该公司获得了190万美元的非摊薄融资，并发行了50万美元的贷款票据。预计MyoVista Insights平台将在2024年底前完成，FDA提交时间定在20...展开全部
2024年9月12日，Heart Test Laboratories, Inc.，也称为HeartSciences，报告了截至2024年7月31日的2025财年第一季度的财务和运营结果。该公司专注于用人工智能技术进行心脏病检测的医疗技术，重点介绍了其MyoVista wavECGTm设备和MyoVista InsightsTm云平台的进展。HeartSciences宣布现金及现金等价物余额为430万美元，股东权益为590万美元。季度结束后，该公司获得了190万美元的非摊薄融资，并发行了50万美元的贷款票据。预计MyoVista Insights平台将在2024年底前完成，FDA提交时间定在2025年下半年。MyoVista wavECGTm设备的FDA 510(k)提交计划顺利进行，预计在2025年初完成。该公司还在联合国大会数字健康研讨会上展示了其技术，并扩大了其知识产权组合。尽管取得了这些进展，HeartSciences报告称在2025财年第一季度没有营收。完整的财务结果已提交给美国证券交易委员会。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间